GPAtlas🧭 When to suspect a problem in a patient on tamoxifen
Tamoxifen is a selective oestrogen receptor modulator (SERM) – an oestrogen antagonist in breast tissue but an agonist in the endometrium, bone and clotting system. This split personality explains both its benefits and its dangers. In UK practice it is licensed for three things: the treatment of breast cancer, the primary prevention of breast cancer in women at moderate or high risk, and the treatment of anovulatory infertility.
Tamoxifen is almost always initiated and monitored in secondary care (oncology, gynaecology or a family-history clinic), but the GP is increasingly asked to continue the prescription under shared care and is usually the first port of call when something goes wrong. Two clinical priorities dominate: recognise the serious adverse effects – venous thromboembolism and endometrial cancer – and prescribe safely around tamoxifen, above all avoiding the drugs that quietly blunt its effect.
| Tissue | Tamoxifen effect → clinical consequence |
|---|---|
| Breast | Antagonist → blocks oestrogen-driven tumour growth (the therapeutic goal). |
| Endometrium | Agonist → hyperplasia, polyps and an increased risk of endometrial cancer (and, rarely, uterine sarcoma). |
| Bone – postmenopausal | Agonist → preserves bone mineral density (bone-protective). |
| Bone – premenopausal | Antagonist → accelerated bone loss; advise on bone health. |
| Clotting system | Prothrombotic → a 2–3× increased risk of VTE (venous thromboembolism) in otherwise healthy women. |
Suspect a tamoxifen-related problem in any patient on the drug who presents with new abnormal vaginal bleeding, symptoms of a clot, visual disturbance, or troublesome menopausal symptoms – and review every new co-prescription for an interaction before issuing it.
Source: MHRA SmPC
🔒 Sign up free to read the full topic
You're viewing a free preview. Create a free account to unlock the rest.
Sign up free →Sample topics are open to everyone in the Free Sample Bundle.